Showing results (2201-2210 of 3,105) with videos related to
Sort By:
Pageof 311
Expert Review of Anticancer Therapy|January 31, 2023
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?Jonathan J Chen, Emily Weg, Jay J LiaoExpert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.Expert Review of Anticancer Therapy|November 14, 2022
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancerShimoli V Barot, Erin Roesch, Jame AbrahamExpert Review of Anticancer Therapy|November 15, 2022
Hot topics in renal cancer pathology: implications for clinical managementAlessia Cimadamore, Anna Caliò, Laura Marandino, et al.Expert Review of Anticancer Therapy|November 14, 2022
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysisQingfeng Ye, Jundan Wang, Da Xu, et al.Expert Review of Anticancer Therapy|November 14, 2022
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?Amir Imran Faisal Hamdi, Soon Hin How, Mohammad Kaisarul Islam, et al.Expert Review of Anticancer Therapy|November 26, 2025
Safety and preliminary efficacy of intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in 100 pediatric patients with solid tumors: a retrospective studyJiarong Wang, Ying Zhang, Xiaorui Wang, et al.Expert Review of Anticancer Therapy|January 12, 2026
Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinomaKristian Egebjerg, Florian Lordick, Lisa L Liu, et al.Expert Review of Anticancer Therapy|January 8, 2026
New horizons for hope of cure in acute myeloid leukemia through immunotherapy: a narrative reviewPasquale Niscola, Valentina Gianfelici, Gloria Pasqualini, et al.Expert Review of Anticancer Therapy|January 18, 2026
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancerRavand Samaeekia, Zhaohui Arter, Misako NagasakaPageof 311